Plant Protein Supplementation Within a Healthy Lifestyle Modulates Plasma Circulating Amino Acids and Improves the Health Status of Overweight Individuals
1 other identifier
interventional
27
1 country
1
Brief Summary
A dietary pattern based on Mediterranean diet has been reported as healthy for humans, as well as doing aerobic exercise regularly, diminishing the development of potential inflammation in subjects. Protein intake has been proposed as nutritional strategy to further improve these positives outcomes in terms of preventing inflammation diseases. In this work, overweight patients followed a Mediterranean diet together with aerobic exercise according to WHO-guidelines and were supplemented with 20 g of hemp protein/day, for twelve weeks. Anthropometric and biochemical measures (including analysis of oligoelements), as well as plasma circulating amino acids were evaluated in each patient at the end of the intervention, to assess whether biologically relevant changes could be observed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable obesity
Started Jan 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2022
CompletedFirst Submitted
Initial submission to the registry
November 2, 2023
CompletedFirst Posted
Study publicly available on registry
November 13, 2023
CompletedNovember 13, 2023
November 1, 2023
1.7 years
November 2, 2023
November 8, 2023
Conditions
Outcome Measures
Primary Outcomes (4)
Evolution of cytokines in intervention
Pro-inflammatory and anti-inflammatory cytokines, including NFα, IL-1β, IL-6, IL-8, IL-10, ICAM-1, MCP-1, leptin, and adiponectin, in plasma will be measured using appropriate methods (EIA, ELISA, and/or Bioplex multiplex system) (mg/dl).
[Time Frame: Up to 6 hours]
Effect of the intervention on subjects' biochemical measures
Total cholesterol and triglycerides (TAG) (mg/dL) were determined by enzymatic methods (CHOD-PAP and GPO-PAP, respectively; Roche Diagnostics, Basel, Switzerland). High density lipoprotein-cholesterol (HDL-C) (mg/dL= was determined after precipitation with phosphotungstic acid. Low-density lipoprotein cholesterol (LDL-C) (mg/dL) was calculated with the Firedewald formula. Blood glucose levels, measured by biochemical procedures (mg/dL).
[Time Frame: Up to 6 hours]
Effect of the intervention on the serum amino acid levels of the subjects.
The amino acid content in plasma (μmol/L) samples analyses were carried out in the University of Sevilla (General Microanalysis Research Service), using an amino acid analyzer BIOCHROM 30, following an amino acid analysis method based on ion exchange chromatography with post column derivatization with ninhydrin.
[Time Frame: Up to 6 hours]
Effect of the intervention on the serum mineral levels of the subjects.
Mineral content (μgl/L) was evaluated using UV or colorimetrics commercial kits (Bioscience Medical).
[Time Frame: Up to 6 hours]
Interventions
All participants followed a low-energy diet (1315 kcal/daily) based on Mediterranean diet for 12 weeks, supplement with 20 g / day of hemp protein. The specific menu was designed by a trainee nutritionist. The program prescribed five meals a day, with the time customized to fit the lifestyle of each patient. Based on the baseline metabolism, the energy and nutritional parameters of every patient were computed. Patients reported the dietary intake data daily. The intervention included face to face visit every two weeks, individual nutrition counseling and education sessions.
Eligibility Criteria
You may qualify if:
- age between 18 and 65 years old
- waist circumference ≥94cm in men and ≥88cm in women
- MET\<4
You may not qualify if:
- prediabetic patients on pharmacotherapy
- subjects suffering from medical issues (e.g., diabetes or another chronic disease)
- smokers
- pregnant or lactating women.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sergio Montserrat de la Pazlead
- Spanish National Research Councilcollaborator
Study Sites (1)
University of Seville
Seville, 41009, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 2, 2023
First Posted
November 13, 2023
Study Start
January 1, 2021
Primary Completion
September 1, 2022
Study Completion
September 1, 2022
Last Updated
November 13, 2023
Record last verified: 2023-11